These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 33746212)

  • 21. Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases.
    Oruç Z; Kaplan MA; Karaağaç M; Özyurt N; Tatlı AM; Kaya AO; Menekşe S; Kut E; Koca S; Sever ÖN; Yasin İ; Ebinç S; Zeynelgil E; Sakin A; Turhal NS; Isikdogan A
    Future Oncol; 2021 May; 17(13):1611-1624. PubMed ID: 33631986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK; Miao R; Vekeman F; Sung J; Cheng WY; Gauthier-Loiselle M; Dhawan R; Duh MS
    Med Oncol; 2017 Aug; 34(9):160. PubMed ID: 28795333
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic immune-inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration-resistant prostate cancer patients.
    Fan L; Wang R; Chi C; Cai W; Zhang Y; Qian H; Shao X; Wang Y; Xu F; Pan J; Zhu Y; Shangguan X; Zhou L; Dong B; Xue W
    Prostate; 2018 Mar; 78(4):250-256. PubMed ID: 29285775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry.
    Kuppen MCP; Westgeest HM; van den Eertwegh AJM; van Moorselaar RJA; van Oort IM; Coenen JLLM; van den Bergh ACMF; Mehra N; Somford DM; Bergman AM; Ten Bokkel Huinink D; Fossion L; Geenen MM; Hendriks MP; van de Luijtgaarden ACM; Polee MB; Weijl NI; van de Wouw AJ; de Wit R; Uyl-de Groot CA; Gerritsen WR
    Eur Urol Oncol; 2021 Aug; 4(4):618-627. PubMed ID: 31601523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of Enzalutamide Rechallenge for Metastatic Castration-Resistant Prostate Cancer.
    Sawazaki H; Kitamura Y; Madoka U; Segawa Y
    Asian Pac J Cancer Prev; 2024 Jun; 25(6):1863-1867. PubMed ID: 38918645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of real-life data of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer.
    Demirci A; Bilir C; Gülbağcı B; Hacıbekiroğlu İ; Bayoğlu İV; Bilgetekin İ; Koca S; Çınkır HY; Akdeniz N; Gül D; Varım C; Demirci U; Öksüzoğlu B
    Sci Rep; 2021 Jul; 11(1):14131. PubMed ID: 34239026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic role of the duration of response to androgen deprivation therapy in patients with metastatic castration resistant prostate cancer treated with enzalutamide or abiraterone acetate.
    Di Stefano RF; Tucci M; Turco F; Samuelly A; Bungaro M; Pisano C; Vignani F; Gallicchio M; Scagliotti GV; Di Maio M; Buttigliero C
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):812-825. PubMed ID: 33603237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
    Perletti G; Monti E; Marras E; Cleves A; Magri V; Trinchieri A; Rennie PS
    Arch Ital Urol Androl; 2015 Jul; 87(2):121-9. PubMed ID: 26150028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.
    Rescigno P; Porta N; Finneran L; Riisnaes R; Figueiredo I; Carreira S; Flohr P; Miranda S; Bertan C; Ferreira A; Crespo M; Rodrigues DN; Gurel B; Nobes J; Crabb S; Malik Z; Ralph C; McGovern U; Hoskin P; Jones RJ; Birtle A; Gale J; Sankey P; Jain S; McLaren D; Chadwick E; Espinasse A; Hall E; de Bono J
    Eur J Cancer; 2024 Jul; 205():114103. PubMed ID: 38729054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
    Thomas C; Brandt MP; Baldauf S; Tsaur I; Frees S; Borgmann H; Jäger W; Bartsch G; Schneider M; Dotzauer R; Neisius A; Haferkamp A
    Int Urol Nephrol; 2018 Oct; 50(10):1821-1827. PubMed ID: 30120678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R; de Bono J; Sternberg CN; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Ozatilgan A; Geffriaud-Ricouard C; Castellano D;
    N Engl J Med; 2019 Dec; 381(26):2506-2518. PubMed ID: 31566937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer.
    Schweizer MT; Zhou XC; Wang H; Bassi S; Carducci MA; Eisenberger MA; Antonarakis ES
    Eur Urol; 2014 Oct; 66(4):646-52. PubMed ID: 24491307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
    Sartor O; George D; Tombal B; Agarwal N; Higano CS; Sternberg CN; Miller K; Jiao X; Guo H; Sandström P; Bruno A; Verholen F; Saad F; Shore N
    Future Oncol; 2022 Jan; 18(1):35-45. PubMed ID: 34636627
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
    Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
    Rouyer M; Oudard S; Joly F; Fizazi K; Tubach F; Jove J; Lacueille C; Lamarque S; Guiard E; Balestra A; Droz-Perroteau C; Fourrier-Reglat A; Moore N;
    Br J Cancer; 2019 Dec; 121(12):1001-1008. PubMed ID: 31719685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
    Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
    JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.
    Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K
    Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
    Vestris PG; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
    Prostate; 2022 Feb; 82(2):269-275. PubMed ID: 34822183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on treatment of metastatic castration-resistant prostate cancer.
    Merseburger AS; Bellmunt J; Jenkins C; Parker C; Fitzpatrick JM;
    Oncologist; 2013; 18(5):558-67. PubMed ID: 23671006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.